Drugs / 68Ga-AAZTA-093
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06437496 | Apr → Jul 2024 | prostate cancer | First Affiliated Hospital of Fujian Medical University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-AAZTA-093 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06437496 ↗ |
| Modality | Diagnostic / imaging agent | “Tracer doses of 68Ga-AAZTA-093 will be used to image lesions of prostate cancer by PET/CT.” NCT06437496 ↗ |
| Route | Intravenous | “Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-AAZTA-093.” NCT06437496 ↗ |